Estradiol Pill — Oral Systemic Estrogen Support

Route: Oral — swallowed tablet.

• Take once daily at the same time each day, with or without food.
• Swallow whole with water; do not crush or chew unless directed by the compounding pharmacist.
• Consistent daily administration is important to maintain stable systemic estradiol/estrone levels.
• If a dose is missed, take as soon as remembered unless it is almost time for the next dose — do not double up.

Dosing is individualized by the prescribing clinician based on indication, symptom severity, and patient response. General pharmacological reference points:

• Oral estradiol doses for menopause symptoms typically range from 0.5 mg to 2 mg once daily.
• Initiate at the lowest effective dose and titrate based on symptom control and serum estradiol.
• Patients with intact uteri require concomitant progestogen — the prescriber determines type, dose, and schedule.
• All dose adjustments are at prescriber discretion; serum estradiol and estrone levels may guide therapy.

• Estradiol (oral): After absorption from the GI tract, oral estradiol undergoes extensive first-pass hepatic metabolism, converting substantially to estrone; circulating estrone and estradiol then bind ERα and ERβ in target tissues. ERα predominates in uterine and mammary tissue; ERβ in bone, vasculature, and brain. Receptor-hormone complexes dimerize, translocate to the nucleus, bind estrogen response elements, and activate gene transcription governing bone remodeling (osteoclast inhibition), hypothalamic thermoregulation (vasomotor symptom reduction), genitourinary epithelial maintenance, and hepatic protein synthesis (SHBG, CRP, clotting factors, triglycerides — notably more pronounced with oral versus transdermal routes).

Clinical Context: Oral estradiol is used for systemic estrogen replacement in peri- and postmenopausal women for relief of vasomotor symptoms, prevention of osteoporosis, and management of genitourinary syndrome of menopause. Compared to transdermal routes, oral estradiol has a larger first-pass hepatic effect, potentially increasing SHBG, triglycerides, and clotting factor synthesis — considerations relevant in patients with hypertriglyceridemia or thromboembolic risk. It remains a widely used option for patients who tolerate or prefer oral administration.

Monitoring Considerations:

• Serum estradiol and estrone at follow-up to confirm therapeutic range.
• Lipid panel: oral estradiol may increase triglycerides — monitor in susceptible patients.
• Endometrial surveillance in non-hysterectomized patients on progestogen.
• Annual mammography per breast cancer screening guidelines.
• Blood pressure and clinical symptom review at least annually; reassess ongoing need.

Contraindications:

• Known or suspected estrogen-dependent malignancies (breast, endometrial cancer).
• Undiagnosed abnormal genital bleeding.
• Active or history of DVT, PE, arterial thromboembolic events (stroke, MI).
• Active liver disease or dysfunction.
• Thrombophilic disorders.
• Pregnancy.

Warnings & Precautions:

• Endometrial cancer: Unopposed estrogen in non-hysterectomized women requires concurrent progestogen.
• Breast cancer: Elevated risk with prolonged use, particularly in combination with progestogen; reassess annually.
• Thromboembolic events: Oral route carries higher VTE risk than transdermal due to hepatic procoagulant factor synthesis; use with caution in high-risk patients.
• Hypertriglyceridemia: Oral estrogen may markedly increase triglycerides in predisposed patients; consider transdermal alternative.

Drug Interactions:

• CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort): decrease estradiol levels.
• CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin): increase estradiol exposure.
• Thyroid hormone: estrogen increases TBG; monitor levothyroxine requirements.
• Anticoagulants: estrogen-induced clotting factor changes may alter anticoagulant requirements.

Common Side Effects: Nausea, breast tenderness and swelling, headache, fluid retention, bloating, mood changes, irregular uterine bleeding or spotting (without adequate progestogen), and weight changes.

Store at controlled room temperature (20–25°C / 68–77°F) in a tightly closed container away from moisture, heat, and light. Do not refrigerate. Keep out of reach of children. Observe the beyond-use date assigned by Genesis Compounding and do not use after this date.

How does an oral estradiol pill differ from a transdermal patch or gel?

Oral estradiol undergoes first-pass hepatic metabolism, resulting in significant conversion to estrone and notable effects on SHBG, triglycerides, and clotting factor synthesis. Transdermal delivery avoids these hepatic effects, providing more stable serum estradiol levels. Prescribers may prefer one route over another based on individual patient risk factors and preferences.

Do I need a progestogen with this tablet?

Yes, if you have an intact uterus — concurrent progestogen is required to prevent unopposed estrogen stimulation of the endometrium, which increases cancer risk. Your prescriber will determine the appropriate progestogen regimen. Women who have had a hysterectomy may use estrogen alone.

Is this FDA-approved?

This is a compounded, patient-specific, prescriber-directed 503A preparation from Genesis Compounding and is not FDA-approved as a finished compounded drug product. FDA-approved oral estradiol tablets are commercially available.

What if I miss a dose?

Take the missed dose as soon as you remember, unless it is close to the time of the next scheduled dose. Do not double doses. Contact your prescriber if doses are frequently missed or if you are unsure how to proceed.

How long will I need to take this medication?

Duration of therapy is individualized. Current guidelines recommend using the lowest effective dose for the shortest duration consistent with treatment goals. Your prescriber will reassess the ongoing need for estrogen therapy at least annually.